Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

25.96 -0.53 (-2.02%)
Delayed Quote Updated: 10:54 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zymeworks Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Completes Acquisition of Theravance Biopharma
From Zymeworks Inc.
Via GlobeNewswire
News headline image
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Acquire Theravance Biopharma, Inc.
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology 
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Outlines Strategic Priorities and Outlook for 2026
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.